SECTOR : Biotech
ENTRY DATE : 2002
EXIT DATE : 2011
BUSINESS : Venture Capital
WEB : www.orexo.com
Specialty pharmaceutical company developing drugs from a proprietary delivery platform
Orexo is a Swedish pharmaceutical company specialised in the development of new patented drugs by combining well-known molecules with innovative technologies, chiefly for the treatment of inflammatory and respiratory conditions. Orexo possesses a large portfolio of products at an advanced development stage and which have already demonstrated therapeutic benefits. In 2007, Orexo merged with Biolipox, a pharmaceutical research & development company focused on inflammatory conditions, through an increase in capital valuing the company at an aggregate amount of $137 million. Orexo (ORX) is listed on the Stockholm Stock Exchange.
(N/a: Initial investment: Omnes Capital purchased a stake in Biolipox in December 2002)